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Summary: A rapid method is described for the determination of plasma levels of bupivacaine used for epidural
analgesia during childbirth. Data obtained in a clinical study are also given.
Bestimmung von niedrigen Bupivacain (Marcain®^Konzentrationen im Plasma während Epiduralanalgesie
Zusammenfassung: Es wird eine schnelle Methode zur Bestimmung des Bupivacains im mütterlichen Blut bei epidura-
ler Analgesic während des Geburtvorgangs beschrieben. Die ermittelten klinischen Daten werden ebenfalls aufgeführt.
Introduction
The increasing demand for epidural analgesia during
childbirth focusses attention on the possible side effects
of the analgesic drug in mother and child. Estimation
of drug levels in maternal and foetal (umbilical cord)
plasma serves to supervise the degree of leakage from the
application site. The drugs used in this type of analgesia
are potent myocardial suppressants and they are able to
cause a constriction of the uterine vessels, in this way
decreasing the utero-placentäl bloodflow (1). A correla-
tion can also be made between cardiac activity of the
child and uterine contraction in the mother (cardio-
tocography) as well as with the general condition of the
newborn, e. g. Apgar score, etc. (2).
In the obstetric department of pur hospital a prospective
study was started on the influence of lumbar epidural
analgesia with bupivacaine-adrenaline on the maternal
and foetal heart rate patterns.
Methods described hitherto for the deter mutation of
bupivacaine iri plasma either require large blood samples
and special equipment (3, 4), or lack sensitivity (5), and
without exception are rather laborious. A high sensitivity,
however, is required because modern techniques of
anaesthesia permit the use of relatively low doses of the
drug with correspondingly low plasma levels. In this
communication we present a modified and rapid estima-
tion procedure using active charcoal for the adsorption
of bupivacaine from acidified plasma.
Materials and Methods
Reagents
1. Active charcoal (BDH Chemicals Ltd, cat. number 33032). A
suspension of 0.4 g in 0.1 litre 0.75 mol/1 HC1 is prepared
before use.
2. Dichloromethane (analytical grade).
3. Standard solution of bupivacaine * HC1, 50 mg/1.
Extraction
In a 10 ml centrifuge tube 1 ml of serum is mixed with 2 ml of
charcoal suspension, vortexed for 30 seconds and centrifuged
2 minutes. The supernatant is removed by suction, 1 ml of
dichloromethane is added, mixed for 45 seconds (Vortex) and
filtered over glass wool into a 3 ml tube. The charcoal is rinsed
with 1 ml of dichloromethane (Vortex) and the combined
organic extracts are evaporated to dryness in a nitrogen stream
at 40 °C.
The residue in the tube is dissolved in 20 of water and 2
of this solution are applied on the gas chromatography column.
Gas chromatography
A Packard-Becker Chromatograph model type 427 is used with
normal flame Ionisation detector, equipped with a silanized
spiral glass column, length 180 cm, internal diameter 0.2 cm,
packed with 3% SE 30 on Gaschrom Q (100/120 mesh) (Applied
Science lab.).
Temperatures: oven 250 °C, detector 300 °C, injection channel
300 °C.
Carrier gas: nitrogen 2.7 kg/cm2 (40 p.s.i.).
Attenuation 10 X 8.
The standard solution (50 mg/1 bupivacaine · HC1) is diluted
tenfold with water prior to use. A sample of 2 of the diluted
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standard (thus containing 10 ng bupivacaine - HC1) is applied
directly on the column.
Calculation
peak height sample 100
u * · u* * A A x 8·9 x 77" x 10 = «β/1 bupivacainepeak height standard 64
Standard 10 ng bupivacaine hydro chloride in 2 μΐ corresponds
to 8.9 ng of the free base; recovery in extraction is 64% (tab. 1);
dilution factor of sample is 10.
Clinical study
As site of puncture for the administration of the drug the third-
lumbar interspace was used and a catheter was introduced 5 .cm
upwards. We injected 10 ml bupivacaine 2.5 g/1 with adrenaline
1/200,000 through the catheter. Every two hours a topping-up
dose of 8 ml of this anaesthetic solution was given. The study
was performed during spontaneous labour in healthy nulliparous
full-term patients with uncomplicated pregnancies.
For the determination of bupivacaine, blood samples were
collected from the ante-cubital vein viz. 10,15, 30, 45, 90 and
120 minutes after the first epidural injection. Foetal E.C.G.,
maternal E.C.G. and intra-uterine pressure were recorded on a
strip-chart-recorder and magnetic tape and processed offline in
a Digital computer system. In one group of 13 patients receiving
epidural analgesia several calculated parameters could be
compared before and following the administration of the
analgesic. Another group of 12 patients was studied following
the same protocol without epidural analgesia. All patients were
in the lateral position.
Tab. 1. Charcoal extraction of added bupivacaine · HC1 from
pooled human plasma. Samples were analysed in dupli-
cate on six consecutive days.
Bupivacaine · HC1 n
added
(Mg/D
% Recovery C.V.
50
100
200
300
mean recovery
12
12
12
12
• 57
64
66
69
64
5.0
4.3
3.8
3.6
4.2
Results
Technical
The procedure described is a modification and combina-
tion of techniques found elsewhere and it results in an
easy determination of bupivacaine in human blood
serum or plasma. The efficacy of the method is espe-
cially due to the extraction procedure. Bupivacaine is
extracted from the acidified plasma by charcoal adsorp-
tion (tab. 1) with an efficiency of 64% in the range
between 50—300 jug/I. In such procedures the co-adsorp-
tion of organic material is often a cause of much inter-
ference in the final detection. To overcome this problem
the organic matter from charcoal is dissolved in dichloro-
methane and evaporated to dryness. From this residue,
bupivacaine easily extracted with water, leaving behind
much organic material which could cause interference.
In this way a "clean" chromatogram is easily obtained
(fig.l).
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Fig. 1. Chromatograms of bupivacaine hydrochloric standard
solution, 10 ng applied on column (a), and serum
extract (b).
There is a linear relation between peak height and con-
centration.
The use of an internal standard is not necessary provided
the analysis is performed in duplicate (C. V. 5% from a
series of duplicates n = 80).
In incidental cases where only one estimation for the
patient is required an external standard of bupivacaine
hydrochloride in plasma is prepared. In serial studies,
however, this would require too much blood from the
patient. In any analysis or series thereof a patient's blank
is prepared from blood taken before the first estimation
of the drug, thus avoiding false results from concomitant
medication. The detection limit (twice the patient's
blank value) is 5 /zg/1.
Clinical
After epidural analgesia a minor decrease in the foetal
heart rate of about 2—4 beats per minute was found. In
the last 1 */2 hours of the first stage, we observed a
decrease in the beat-to-beat variations of the foetal heart
rate in the epidural group. It is our opinion that there
might be a correlation between these changes in foetal
heart rate patterns and the bupivacaine levels.
The bupivacaine levels in 13 patients were measured and
the results given in figure 2.
Discussion
Because the time required for a single analysis is only
about 15 minutes, the method is most suitable for moni-
toring blood levels, even during labour.
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Fig. 2. Bupivacaine levels (means ± s.d.) in maternal blood plasma
after administration of 10 ml 2.5 g/1 solution (25 mg) of
the drug; the solution contains also adrenalin 5 m g/1.
The rather small amount of plasma needed for the estima-
tion and the rapid availability of results is certainly of
great help to the obstetrical department. The administra-
tion of bupivacaine can be correlated with the plasma
levels in the maternal blood. Overloading the patients
can be prevented in this way. Another advantage is that
changes in the cardiotocogram can be considered in
combination with bupivacaine levels, thus distinguishing
the administration of bupivacaine from other causes of
change in foetal heart rate patterns.
At present a comparison is being made between larger
groups with and without bupivacaine during labour.
Results of this clinical study with more detailed informa-
tion about the obstetrical data will be reported else-
where.
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